Skip to main content
PSNL logo

Personalis, Inc. (PSNL) Stock: Price, Forecast & Analyst Target

Personalis, Inc. (PSNL) — MoonshotScore 23/100 (Weak band), calculated Oct 26, 2026. Price $15.88 (+0.19%), as of the Oct 26, 2026 trading session; market cap $1.70B.

Educational signal · not a buy or sell recommendation · How to read this

$15.88 +$0.03 (+0.19%) Market Cap $1.70B

Personalis, Inc. · PSNL · NASDAQ

Personalis, Inc. is a cancer genomics company providing sequencing and data analysis services. Their NeXT platform and related products support the development of cancer therapies and large-scale genetic research programs.

Price as of Oct 26, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Personalis (PSNL)

Weak
Business Quality Thin (20)
Financial Safety Strained (30)
Valuation Full (41)
Growth Durability Shrinking (7)
Momentum Surging (97)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.

  • quarterly revenue $22M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 5 of 8
  • Altman Z 9.94 · Piotroski F 1

Holding back: weak fundamentals, balance-sheet strain, soft growth

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PSNL (42 recorded, newest six shown)
RecordedScoreBand
27Weak
23Weak
23Weak
23Weak
23Weak
23Weak

The score was 23 in the stored Oct 24, 2026 snapshot and remains 23 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Financial Safety +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$15.88
Change on the day+0.19%
52-week range$4.96 – $18.89
Market capitalisation$1.70B
Price / earnings (trailing)-6.12
Shares traded on the day954.5K

Price & events

Other perspectives

Council score for Personalis (PSNL): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Growth Durability Negative
Momentum Strong
Business Quality Weak
Financial Safety Weak
Valuation Neutral

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Moderate
ROE Negative
Gross Margin Weak

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 26, 2026, except a card that shows its own read date.

Watch the PSNL film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is Personalis (PSNL), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Personalis, Inc. (PSNL) is listed on NASDAQ. It employs 260 people and is led by Christopher Hall. In Q2 FY2026 it reported revenue of $22M and net income of -$32M. The market values it at $1.70B.

2 · Latest results

What do the latest results show for Personalis (PSNL)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $22M. Against analyst estimates the company has EPS beat 5 of 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$22M-$32M-$0.30 (diluted)
Q1 FY2026$15M-$30M-$0.29 (diluted)
Q4 FY2025$17M-$24M-$0.26 (diluted)
Q3 FY2025$14M-$22M-$0.24 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Personalis (PSNL)?

Short answer

The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals, balance-sheet strain, soft growth. The distress and quality screens read Altman Z 9.94 · Piotroski F 1. Trailing ratios: ROE -46.5% · ROA -34.3% · current ratio 5.28 · earnings yield -6.4% · free-cash-flow yield -6.0%.

Data-derived red flags

  • Negative return on equity (-46.5%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Personalis (PSNL)?

Short answer · as of

Current published price targets run low $9.00 · high $17.00 · consensus $14.95 · median $16.25 against a quoted price of $15.88 (as of Oct 26, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Personalis compare with its peers?

Short answer

Personalis's score ranks 2nd of 2 in the bounded comparison shown, against 1 same-model peer. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Guardant Health, Inc. (GH) Named competitor$173.25 Oct 26, 2026$23.3B36 5-pillar Oct 26, 2026
Personalis (PSNL) — this page$15.88$1.70B23
Exact Sciences Corporation (EXAS) Named competitor$104.91 Sep 11, 2026$20.0B— Model unavailable
NeoGenomics, Inc. (NEO) Same industry, near in market value$16.69 Date unavailable$2.17B— Model unavailable
OPKO Health, Inc. (OPK) Same industry, near in market value$1.65 Date unavailable$1.23B— Model unavailable
Neogen Corporation (NEOG) Same industry, near in market value$12.21 Date unavailable$2.67B— Model unavailable
Castle Biosciences, Inc. (CSTL) Same industry, near in market value$33.48 Date unavailable$1.02B— Model unavailable
CareDx, Inc (CDNA) Same industry, near in market value$69.21 Date unavailable$3.58B— Model unavailable
Myriad Genetics, Inc. (MYGN) Same industry, near in market value$6.02 Date unavailable$576M— Model unavailable
BillionToOne, Inc. (BLLN) Same industry, near in market value$107.77 Date unavailable$5.09B— Model unavailable
Sotera Health Company (SHC) Same industry, near in market value$18.10 Date unavailable$5.16B— Model unavailable
Fulgent Genetics, Inc. (FLGT) Same industry, near in market value$20.22 Date unavailable$556M— Model unavailable
Aclaris Therapeutics (ACRS) Same industry, near in market value$3.75 Date unavailable$552M— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$9.00 – $17.00
Consensus target
$14.95
Median target
$16.25

Consensus record · Captured .

Measured against a quoted price of $15.88 (as of Oct 26, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 18, 2026

Transactions
46
Identified insiders
10
Purchases
0
Sales
12
Other transactions
34

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What has been published about Personalis (PSNL)?

Read these with our analysis →

Personalis Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the PSNL research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for PSNL?

PSNL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Personalis, Inc. is a cancer genomics company providing sequencing and data analysis services.

Is PSNL a good stock to buy?

Stock Expert AI does not rate PSNL buy, sell or hold. Personalis, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PSNL stock price today?

The last price recorded on this page for Personalis, Inc. (PSNL) is $15.88, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PSNL price target?

The analyst consensus price target for Personalis, Inc. (PSNL) is $14.95 (range $9.00 to $17.00, median $16.25), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does Personalis, Inc. do?

Personalis, Inc. is a cancer genomics company that provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs.

What are the key factors to evaluate for PSNL?

Personalis, Inc. (PSNL) holds a MoonshotScore in the low range. Analysts target $14.95 (-6%). Partnerships with Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center demonstrate strategic collaborations to expand research and market reach. Not financial advice.

How frequently does PSNL data refresh on this page?

PSNL's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PSNL's recent stock price performance?

Personalis, Inc. (PSNL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced NeXT Platform for comprehensive genomic analysis. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PSNL overvalued or undervalued right now?

Personalis, Inc. (PSNL) is loss-making, so its trailing P/E is negative (-6.12x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $14.95 (-6%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (22 figures)

The 22 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 14 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$15.88FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T20:04:44.312Z.
px.changeChange on the day+0.19%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$1.70BFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:00.000Z. Captured from FMP at 2026-10-26T20:04:42.876Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars+$0.03FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$22MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.pePrice / earnings (trailing)-6.12FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day954.5KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2026-$32MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
earn.ptStored analyst price targetslow $9.00 · high $17.00 · consensus $14.95 · median $16.25FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied
earn.pt_rangeAnalyst price target, low to high$9.00 – $17.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$14.95FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$16.25FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied
own.insidersInsider transactions via FMP46 transactions · 0 purchases, 12 sales, 34 other transactions · 10 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 18, 2026FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 6 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 5 of 8UNRECORDEDStored earnings-history observation — Captured 2026-10-12 · Expired observation
fin.scoresDistress and quality screensAltman Z 9.94 · Piotroski F 1UNRECORDEDStored financial-scores observation — Captured 2026-10-24 · Expired observation
px.range5252-week range$4.96 – $18.89UNRECORDEDStored company-profile observation — Captured 2026-10-20
id.employeesEmployees260UNRECORDEDStored company-profile observation — Captured 2026-10-20
id.ceoChief executiveChristopher HallUNRECORDEDStored company-profile observation — Captured 2026-10-20
fin.ratiosReturn and yield ratios (trailing twelve months)ROE -46.5% · ROA -34.3% · current ratio 5.28 · earnings yield -6.4% · free-cash-flow yield -6.0%—UNRECORDEDStored key metrics — Date unknown

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v223 of 100 · Weak · pillars 20 / 30 / 41 / 7 / 97OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement23 (stored snapshot Oct 24, 2026) → 23 (current publication computed Oct 26, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.